Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of DZD8586 in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
CTR20240120Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Apr 2024; status: active.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20240120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240120.